With Healthcare (XLV) up 3.2%, this looks like a sector-led move rather than a company-specific surprise.
The healthcare sector experienced a significant rally, with the XLV ETF climbing over 3%, driven by a confluence of positive factors. Upgraded earnings forecasts for S&P 500 healthcare companies project double-digit growth, attracting new institutional investment. This enthusiasm is bolstered by a more favorable regulatory environment, a healthy pace of FDA drug approvals, and an increase in M&A activity within the sector. Investors also appear to be rotating out of previously high-flying technology and AI-related stocks into healthcare, which is seen as offering more attractive valuations and defensive growth characteristics. Positive, company-specific news, such as Moderna's promising cancer vaccine trial results, further contributed to the sector's strong performance.